89bio, Inc. (NASDAQ:ETNB - Get Free Report)'s share price rose 4.9% during trading on Friday . The stock traded as high as $9.97 and last traded at $10.09. Approximately 1,072,013 shares were traded during mid-day trading, a decline of 28% from the average daily volume of 1,484,057 shares. The stock had previously closed at $9.62.
Analyst Ratings Changes
ETNB has been the subject of several recent analyst reports. Citigroup initiated coverage on 89bio in a research report on Thursday, March 13th. They issued a "buy" rating and a $25.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $21.00 price objective (down previously from $29.00) on shares of 89bio in a research report on Friday, February 28th. Cantor Fitzgerald upgraded 89bio to a "strong-buy" rating in a report on Wednesday, April 30th. Weiss Ratings restated a "sell (d-)" rating on shares of 89bio in a report on Wednesday, June 11th. Finally, The Goldman Sachs Group assumed coverage on 89bio in a report on Friday, March 14th. They set a "neutral" rating and a $11.00 price target for the company. Two analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $26.43.
View Our Latest Stock Analysis on ETNB
89bio Stock Performance
The company has a market cap of $1.47 billion, a price-to-earnings ratio of -3.45 and a beta of 1.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.66 and a quick ratio of 11.66. The stock has a 50-day moving average price of $8.17 and a 200 day moving average price of $8.27.
89bio (NASDAQ:ETNB - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.01. During the same period last year, the business posted ($0.54) earnings per share. As a group, analysts anticipate that 89bio, Inc. will post -3.19 EPS for the current fiscal year.
Insider Activity at 89bio
In related news, insider Quoc Le-Nguyen sold 15,329 shares of 89bio stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $5.95, for a total value of $91,207.55. Following the sale, the insider now owns 328,323 shares of the company's stock, valued at approximately $1,953,521.85. This trade represents a 4.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.60% of the stock is owned by insiders.
Institutional Investors Weigh In On 89bio
A number of hedge funds and other institutional investors have recently bought and sold shares of ETNB. CWM LLC grew its stake in 89bio by 9,265.1% in the first quarter. CWM LLC now owns 5,900 shares of the company's stock valued at $43,000 after purchasing an additional 5,837 shares in the last quarter. Federated Hermes Inc. grew its stake in 89bio by 206.9% in the fourth quarter. Federated Hermes Inc. now owns 6,283 shares of the company's stock valued at $49,000 after purchasing an additional 4,236 shares in the last quarter. Quarry LP bought a new position in 89bio in the fourth quarter valued at approximately $55,000. GAMMA Investing LLC grew its stake in 89bio by 4,898.7% in the first quarter. GAMMA Investing LLC now owns 7,648 shares of the company's stock valued at $56,000 after purchasing an additional 7,495 shares in the last quarter. Finally, Sandia Investment Management LP grew its stake in 89bio by 28.5% in the fourth quarter. Sandia Investment Management LP now owns 11,286 shares of the company's stock valued at $88,000 after purchasing an additional 2,500 shares in the last quarter.
89bio Company Profile
(
Get Free Report)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
Featured Stories
Before you consider 89BIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 89BIO wasn't on the list.
While 89BIO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
